NovalGen is a clinical-stage biotechnology company focused on developing innovative multi-specific biologics aimed at improving patient outcomes in autoimmune, oncological, and other immunological disorders. Central to their approach is the proprietary Autoregulation (AR) technology, which allows for the creation of safer and more effective immunotherapies. This platform integrates self-regulating capabilities into various therapeutic modalities, enabling the drugs to adjust their activity based on the patient's response. By doing so, NovalGen aims to minimize the toxicities often associated with traditional immunotherapies, thereby enhancing the therapeutic index and improving overall patient outcomes.

The company’s lead programs, including NVG-111 and the next-generation NVG-222, utilize ROR1-targeting bispecific antibodies designed to engage T cells in a more effective manner. NVG-111 has shown promising clinical results in treating hematological malignancies, while NVG-222 is engineered to extend the half-life of the treatment, allowing for less frequent dosing and improved safety. NovalGen's innovative approach to targeting the Frizzled domain of ROR1, combined with their autoregulation technology, positions them at the forefront of developing next-generation immunotherapies that could significantly alter the treatment landscape for patients with challenging diseases.

United Kingdom

NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond

NovalGen

Company Details